Parabilis Medicines, Inc. Stock: price and insider trades · United States

Parabilis Medicines, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 15 filings came from 3 insiders.

Every open-market trade in the period is a purchase: 6 purchases worth €6.1M, from 1 insider, and not a single sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. One trade stands out by size: a purchase of €2.3M from RA Capital Management, L.P., disclosed on 22 July 2026, or 0.066% of market capitalisation. Those buying include 1 senior executive.

The latest purchase dates back some time: it was published 88 days ago, on 22 July 2026. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.

With 15 filings in twelve months, the company is quieter than the median of 19 filings across the 5,813 companies we follow on the same exchange. Over the whole record (from 2026), the tally stands at 6 purchases and no sales.

Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.